Clinical Challenges: Beyond CDK4/6 Inhibition in Advanced HR-Positive Breast Cancer
The emergence of CDK4/6 inhibitors has reshaped the therapeutic landscape for advanced hormone receptor (HR)-positive breast cancer, extending progression-free survival (PFS) and in some cases overall survival (OS) when combined with first-line endocrine therapy. Unfortunately, most patients eventually progress, and the next step after CDK4/6 inhibition is perhaps “the hottest topic that all of us […]
Is Omitting Radiation Therapy in Low-Risk Breast Cancer a Good IDEA?
SAN ANTONIO — Postmenopausal women with genomically low-risk early hormone receptor (HR)-positive breast cancer had a low risk of recurrence with endocrine therapy alone after lumpectomy, a randomized trial showed. The 5-year overall survival (OS) and cancer-specific survival (CSS) rates were 100% without adjuvant radiation therapy (RT) in 186 women ages 50-69 followed for at […]